OMX Ventures

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Tagomics specializes in epigenetic biomarker discovery using epigenetic chemical modifications. These modifications provide an additional layer of information to DNA, making them more dynamic and sensitive to lifestyle factors, environment, and disease. This enables early detection of common cancers like colorectal cancer.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

Founded in 2021, Aperiam Bio specializes in protein engineering. It partners with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins using computer vision algorithms and deep learning optimization.

VedaBio is a developer of advanced molecular diagnostics equipment that focuses on enhancing the accuracy and efficiency of point-of-care testing. The company's innovative platform enables near-instant molecular detection of highly multiplexed analytes, achieving performance comparable to traditional polymerase chain reaction (PCR) methods without the need for target amplification. By streamlining complex testing processes, VedaBio aims to provide medical researchers and healthcare professionals with reliable and cost-effective solutions for antigen testing, ultimately transforming the landscape of molecular biology and diagnostics.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA constructs. The company aims to harness the potential of genome engineering to create innovative solutions in medicine, enhancing the ability to manipulate genetic material for therapeutic purposes. By developing technologies that enable precise DNA writing, Replay seeks to redefine the landscape of genetic research and its applications, ultimately contributing to improved health outcomes and the treatment of various diseases.

1859, Inc. is a biotechnology company established in 2019 and based in San Diego, California. The company specializes in the discovery and development of next-generation therapeutics, utilizing an advanced artificial intelligence-powered drug discovery platform. This innovative platform integrates combinatorial chemistry, pico-scale activity-based screening, and artificial intelligence to generate millions of empirical data points. By doing so, 1859 aims to accelerate the process of discovering novel small molecule therapeutics, thereby enhancing the capabilities of pharmaceutical companies in developing new medicines.

Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Founded in 2020, Sestina Bio is a biotechnology company dedicated to developing innovative synthetic biology platforms. The company aims to tackle global challenges by integrating advanced technologies such as synthetic biology, data sciences, and bio-analytical systems.

Finch Therapeutics develops microbial therapies to treat serious medical conditions driven by microbiome disruption. It uses machine learning algorithms to identify microbes from successful clinical datasets, enabling early retirement of translational risk.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Matterworks is a developer of an artificial intelligence platform focused on advancing the field of metabolomics within the life sciences. The company's technology enhances analytical capabilities, allowing scientific researchers to conduct faster and more comprehensive metabolomic screenings. By facilitating the discovery and engineering processes, Matterworks aims to accelerate scientific progress and support innovation in various biological applications.